share_log

Viking Therapeutics | 10-Q: Q2 2024 Earnings Report

Viking Therapeutics | 10-Q: Q2 2024 Earnings Report

Viking Therapeutics | 10-Q：2024财年二季报
美股SEC公告 ·  2024/07/24 14:05

Moomoo AI 已提取核心信息

Viking Therapeutics reported financial results for Q2 2024, with a net loss of $22.3 million ($0.20 per share) compared to $19.2 million ($0.19 per share) in Q2 2023. Research and development expenses increased 70.8% to $23.8 million, primarily due to expanded clinical studies and manufacturing activities for drug candidates. The company ended the quarter with $942.3 million in cash and investments.The company made significant progress across its pipeline, including positive Phase 2 VENTURE study results for VK2735 in obesity and Phase 2b VOYAGE trial results for VK2809 in NASH. General and administrative expenses rose 4.7% to $10.3 million, while interest income increased substantially to $11.8 million from $4.5 million in the prior year period.Looking ahead, Viking plans to initiate a Phase 3 trial for subcutaneous VK2735 in obesity and a Phase 2 trial for oral VK2735 later in 2024. The company believes its current cash position will fund operations through at least September 2025. Management continues to focus on advancing its metabolic disorder pipeline while maintaining a strong financial position.
Viking Therapeutics reported financial results for Q2 2024, with a net loss of $22.3 million ($0.20 per share) compared to $19.2 million ($0.19 per share) in Q2 2023. Research and development expenses increased 70.8% to $23.8 million, primarily due to expanded clinical studies and manufacturing activities for drug candidates. The company ended the quarter with $942.3 million in cash and investments.The company made significant progress across its pipeline, including positive Phase 2 VENTURE study results for VK2735 in obesity and Phase 2b VOYAGE trial results for VK2809 in NASH. General and administrative expenses rose 4.7% to $10.3 million, while interest income increased substantially to $11.8 million from $4.5 million in the prior year period.Looking ahead, Viking plans to initiate a Phase 3 trial for subcutaneous VK2735 in obesity and a Phase 2 trial for oral VK2735 later in 2024. The company believes its current cash position will fund operations through at least September 2025. Management continues to focus on advancing its metabolic disorder pipeline while maintaining a strong financial position.
Viking Therapeutics发布了2024年第二季度的财务结果，净亏损为$2230万（每股$0.20），相比之下，2023年第二季度的净亏损为$1920万（每股$0.19）。研发费用增加了70.8%，达到了$2380万，主要由于扩大了临床研究和药物候选者的制造业-半导体活动。公司在本季度结束时现金和投资总额为$94230万。公司在其产品管线中取得了显著进展，包括VK2735在肥胖症的积极Phase 2 创业公司的研究结果，以及VK2809在NASH中的Phase 20亿 VOYAGE试验结果。一般和行政费用上升了4.7%，达到了$1030万，而利息收入则大幅增加，达到了$1180万，...展开全部
Viking Therapeutics发布了2024年第二季度的财务结果，净亏损为$2230万（每股$0.20），相比之下，2023年第二季度的净亏损为$1920万（每股$0.19）。研发费用增加了70.8%，达到了$2380万，主要由于扩大了临床研究和药物候选者的制造业-半导体活动。公司在本季度结束时现金和投资总额为$94230万。公司在其产品管线中取得了显著进展，包括VK2735在肥胖症的积极Phase 2 创业公司的研究结果，以及VK2809在NASH中的Phase 20亿 VOYAGE试验结果。一般和行政费用上升了4.7%，达到了$1030万，而利息收入则大幅增加，达到了$1180万，相比之下去年同期为$450万。展望未来，Viking计划于2024年晚些时候开始VK2735的皮下Phase 3试验以及VK2735的口服Phase 2试验。公司相信其当前的现金状况将能支撑运营至少到2025年9月。管理层继续专注于推进其代谢疾病的产品管线，同时保持强劲的财务状况。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

独立文件7  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Portage Biotech
    PRTG
    -- 9.600
    莱斯康制药
    LXRX
    -- 0.571
    DBV Technologies
    DBVT
    -- 6.200
    NeOnc Technologies
    NTHI
    -- 16.550
    Alumis
    ALMS
    -- 5.640
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日